← back to search

Claes Karlsson

Karolinska University Hospital · SE
Area of research
Genetics · Pathology and Forensic Medicine
Research interest
Research interests include Chronic Lymphocytic Leukemia Research, Lymphoma Diagnosis and Treatment, Immunodeficiency and Autoimmune Disorders, and Cancer Genomics and Diagnostics.
h-index
15
citations
1,410
works
38
NIH funding
primary concept
email

Recent publications

Bridging the Divide: A Review on the Implementation of Personalized Cancer Medicine
Journal of Personalized Medicine 2024cited by 21position: middledoi
The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology
Nature Cancer 2022cited by 127position: middledoi
Author Correction: The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology
Nature Cancer 2022cited by 7position: middledoi
Implementation of a Clinical Decision Support System for Precision Oncology across an Academic Network
Research Square 2021cited by 1position: middledoi
Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal
Nature Medicine 2020cited by 88position: middledoi
Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma
Leukemia 2018cited by 116position: middledoi
Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort
Haematologica 2018cited by 61position: middledoi
Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group
Haematologica 2016cited by 114position: middledoi
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study
The Lancet Oncology 2015cited by 409position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Anna Asklid · Karolinska University Hospital2 papers (2016–2018)Maria Winqvist · Karolinska University Hospital2 papers (2016–2018) · 2 papers (2016–2018) · 2 papers (2016–2018)Karin Karlsson · Uppsala University2 papers (2016–2018)Mattias Mattsson · Uppsala University Hospital2 papers (2016–2018)Jeanette Lundin · Karolinska University Hospital2 papers (2016–2018) · 2 papers (2016–2018)Anders Österborg · Karolinska University Hospital2 papers (2016–2018)Lotta Hansson · Karolinska University Hospital2 papers (2016–2018)Richard Rosenquist · Karolinska University Hospital1 papers (2018–2018)Ingemar Ernberg · Karolinska Institutet1 papers (2024–2024)Lennart Blomqvist · Karolinska University Hospital1 papers (2024–2024)Michele Masucci · Karolinska Institutet1 papers (2024–2024) · 1 papers (2016–2016) · 1 papers (2018–2018) · 1 papers (2018–2018)